1MATCRSPastPres

“Experience is the child of thought, and thought is the child of action.”  Benjamin Disraeli

Select Achievements and Experience

NatBioProteinDeliverySemple Dr. Tracy receives the CRS Distinguished Service Award in July 2013 from CRS President, Prof. I. Tucker (left), and Immediate Past President, Prof. K. Kataoka (right)

  • Advanced nine medicines to the clinic, four of which have been commercialized:
    • Nutropin® Depot (protein)
    • Risperdal® Consta (small molecule)
    • Vivitrol® (small molecule)
    • Bydureon® (peptide)
  • At Alkermes, Inc., developed the first long-acting protein approved by the FDA and commercialized (Nutropin® Depot)
  • Led an international alliance of academic and industry partners while at Alnylam, Inc. that brought new nanotechnology-based RNA products to the clinic and enabled human clinical proof of concept for RNAi and a growing pipeline of RNA-based clinical programs
    • Advanced the first dual targeted RNAi based therapeutic to the clinic
  • Fellow, American Institute for Medical and Biological Engineering (AIMBE) www.aimbe.org
  • Adjunct Associate Professor, Department of Pharmaceutical Sciences, Northeastern University
  • Education
    • Greater Boston Executive Program, MIT-Sloan School of Management
    • Ph.D., Chemistry, Stanford University
    • M.S., Chemical Engineering, Stanford University (Tau Beta Pi Fellow)
    • B.S., Chemical Engineering, University of Illinois (Summa cum Laude)
BioConsulting Briefs
MATCRS2cropped2-133x106
Mark Tracy Receives CRS Distinguished Service Award
Mark A. Tracy was awarded the prestigious Distinguished Service Award of the Controlled Release Soci ( Read More )
MATCRS2cropped2-133x106
Interview with Mark Tracy
Insights into the Biopharmaceutical Industry ( Read More )
home-img
Interspecies information website
This website is an excellent resource for physiological, anatomical and biochemical parameters for a ( Read More )
innerpage-slide
Good review practices for INDs
A helpful new FDA document was recently issued describing the FDA’s good review practices for ( Read More )
home-img
Approval of Kynamro
The January 2013 approval of Kynamro (mipomirsen) marks the first systemically administered antisens ( Read More )